No Data
No Data
Amazon To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Wednesday
4D Molecular Therapeutics Analyst Ratings
BofA Securities Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Cuts Target Price to $46
Express News | 4D Molecular Therapeutics Inc : BofA Global Research Cuts Price Objective to $46 From $79
Express News | 4Dmt Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in Iovs
We Think 4D Molecular Therapeutics (NASDAQ:FDMT) Can Afford To Drive Business Growth